Abstracts tagged "Biomarkers"

Abstract Number: 1303 • 2019 ACR/ARP Annual Meeting
Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA
Dawn McGuire¹, Michael Bowes ², Alan Brett ², Neil Segal ³, Meghan Miller ⁴, David Rosen ⁴ and Yoshinari Kumagai ⁴, ¹OrthoTrophix, Orinda, CA, ²Imorphics, Manchester, England, United Kingdom, ³University of Kansas Medical Center, Kansas City, KS, ⁴OrthoTrophix, Oakland, CA
Background/Purpose: Pathological bone shape changes in the femur precede cartilage changes in knee OA and predict disease onset and progression to joint failure (Neogi 2013;…
Abstract Number: 2187 • 2019 ACR/ARP Annual Meeting
A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment
Yunyun Luo ¹, Jonathan Samuels ², Svetlana Krasnokutsky ³, Inger Byrjalsen ¹, Jeppe Andersen ⁴, Asger Bihlet ⁵, Yi He ¹, Morten Karsdal ⁶, Steven Abramson ⁷, Mukundan Attur ³ and Anne Bay-Jensen¹, ¹Nordic Bioscience, Herlev, Denmark, ²NYU Langone Medical Center, New Yort, NY, ³NYU School of Medicine and NYU Langone Orthopedic Hospital, New York City, NY, ⁴Nordic Bioscience, Clinical development, Herlev, Denmark, ⁵Nordic Bioscience Clinical Development, Herlev, Denmark, ⁶Nordic Bioscience, Copenhagen, Denmark, ⁷NYU School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: Osteoarthritis (OA) is a highly heterogeneous disease, which suggest that multiple endotypes exist. Identification and characterization of such endotypes may assist in precision medicine…
Abstract Number: 1357 • 2019 ACR/ARP Annual Meeting
Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity
Joshua Baker¹, Jeffrey Curtis ², David Chernoff ³ and Michael George ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²University of Alabama at Birmingham, Birmingham, AL, ³Myriad Genetics, Inc, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: Obesity and excess adiposity influence inflammatory markers and bias assessments of disease activity, most notably among women. A leptin-adjusted multi-biomarker disease activity (MBDA-LA) score…
Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Melanie Hagen¹, Koray Tascilar ², Michaela Reiser ³, Judith Haschka ⁴, Arnd Kleyer ⁵, Larissa Valor ⁶, Bernhard Manger ⁷, Georg Schett ⁸ and Jürgen Rech ⁹, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Karl Landsteiner Institute for Gastroenterology and Rheumatology, St. Vincent Hospital Vienna, II Medical Department, Vienna, Austria, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, ⁷Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
Abstract Number: 781 • 2018 ACR/ARHP Annual Meeting
Simultaneous Identification of Two Biomarkers in ACTIVE LUPUS Nephritis: Autophagy in Treg CELLS and Prolactin Receptors in B Lymphocytes
Luis J. Jara-Quezada¹, Emma Zurita², Ana Durán², Antonio Sanchez³, Reyna Bustamante³, Gabriela Medina⁴, Miguel A Saavedra⁵, María Pilar Cruz-Dominguez³, Olga Vera-Lastra⁶, María Pilar Jiménez-Arellano⁷, Michel Augusto Martínez-Bencomo³ and Azucena Rodriguez², ¹Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional,, Mexico, Mexico, ²Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional,, Mexico City, Mexico, ³Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional "La Raza", Mexico City, Mexico, ⁴Clinical Research Unit, Hospital de Especialidades Centro Medico La Raza,IMSS, Mexico City, Mexico, ⁵Novartis Farmaceutica, Calz de Tlaplan 1779, Mexico, Mexico, ⁶Rheumatology, Instituto Mexicano Seguro Social, Mexico City, Mexico, ⁷Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional "La Raza", Mexico CIty, Mexico
Background/Purpose: Recent studies suggest that autophagy defects contributes to systemic lupus erythematosus (SLE) pathogenesis. Prolactin (PRL) is associated with active SLE and stimulates the immune…
Abstract Number: 1255 • 2018 ACR/ARHP Annual Meeting
Elevated Serum Globulin Gap As a Reliable and Cost-Savings Marker of Inflammation in Patients with Systemic Rheumatic Diseases
William Stohl¹, Beatrice Kenol², Andrew Kelly², Aditi Ananth Correa² and Richard Panush³, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²Keck School of Medicine of University of Southern California, Los Angeles, CA, ³Rheumatology, Keck School of Medicine of University of Southern California, Los Angeles, CA
Background/Purpose: In clinical practice, the two most commonly used markers of systemic inflammation are the serum CRP level and ESR. The economic costs of these…
Abstract Number: 1573 • 2018 ACR/ARHP Annual Meeting
Salivary Dysbiosis Correlates with Clinical Status of Anti-Ro Positive Mothers of Children with Neonatal Lupus
Robert M. Clancy¹, Carl Langefeld², Hannah C. Ainsworth³, Martin Blaser⁴, Peter M. Izmirly⁵, Corey Lacher¹, Miranda C Marion⁶, Mala Masson¹, Gregg Silverman⁷ and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Director of the NYU Human Microbiome Program, NYU School of Medicine, New York, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY, ⁶Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁷Dept of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Neonatal lupus is linked to the presence of circulating anti-Ro antibodies in the mother. These antibodies are present in asymptomatic individuals, who in a…
Abstract Number: 2035 • 2018 ACR/ARHP Annual Meeting
Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
Christian S. Thudium¹, Anne C. Bay-Jensen¹, Suntara Cahya², Ernst R. Dow², Morten A. Karsdal¹, Alisa E. Koch², Wenling Zhang² and Robert J. Benschop², ¹Nordic Bioscience, Herlev, Denmark, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2. In the phase 3 study RA-BUILD (NCT01721057), once-daily bari yielded…
Abstract Number: 2937 • 2018 ACR/ARHP Annual Meeting
Anti-Vinculin Antibodies in Systemic Sclerosis (SSc): A Potential Biomarker Linking Vascular and Gastrointestinal System Involvement in Two Phenotypically Distinctive SSc Groups
Yossra A Suliman¹, Suzanne Kafaja², Gianluca Bagnato³, Mohamed Alemam⁴, Isela Valera⁵, Walter Morales⁶, Mark Pimentel⁷, Francesco Del Galdo⁸ and Daniel E. Furst⁹, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ³Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Clinical Pathology and Laboratory Medicine Department, Lecturer, Qena, Egypt, ⁵Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ⁶GI Motility Program, Research associate, Los Angeles, CA, ⁷Gastrointestinal, Cedar Sinai Medical Center, Los Angeles, CA, ⁸Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Vinculin is a cytoskeletal protein that plays a major role in cell-cell and cell-extracellular matrix adhesion thus regulating cell growth, migration and function of…
Abstract Number: 783 • 2018 ACR/ARHP Annual Meeting
Procalcitonin and CXCL9 As Potential Biomarkers for Pneumonia in Patients with Systemic Lupus Erythematosus
Hilda Fragoso-Loyo¹, Andrea Hinojosa-Azaola¹, Ricardo Ríos-Corzo², John Hernandez-Flores³, Mariana Lopez-Lopez¹, Ariadna Díaz-Mora¹, Alma Lilia Pulido-Ramírez², Jose Sifuentes-Osornio³, María de Lourdes Guerrero-Almeida⁴, Luis Alfredo Ponce de León-Garduño⁴, Eduardo Carrillo-Maravilla⁵, Luis Llorente¹ and Yemil Atisha-Fregoso^6,7, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Medicine Division, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴Infectious Diseases Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Medicina Interna, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, ⁶Instituto Tecnológico de Estudios Superiores de Monterrey, Mexico City, Mexico, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Pneumonia is an important cause of death in patients with SLE. In general population, recommendations encourage the use of procalcitonin for management of pneumonia,…
Abstract Number: 1332 • 2018 ACR/ARHP Annual Meeting
Proteomic Discovery Analysis Identifies Unique Proteins and Pathways Correlating with Different Clinical Activity and Damage Measures in Juvenile Dermatomyositis (JDM)
Hanna Kim¹, Angelique Biancotto², Foo Cheung², Terrance P. O'Hanlon³, Yan Huang⁴, Frederick W. Miller³, Raphaela Goldbach-Mansky⁴ and Lisa G. Rider⁵, ¹Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD, ³Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁴Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁵Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: JDM is a complex heterogeneous autoimmune disease. To define biomarkers and better understand JDM pathogenesis, aptamer-based proteomic technology was used to mine the serum…
Abstract Number: 1589 • 2018 ACR/ARHP Annual Meeting
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Lihi Eder¹, Vinod Chandran², Iain B. McInnes³, Richard J. Cook⁴, Dafna D Gladman⁵, Paul Welsh⁶, Naveed Sattar⁷ and Paula Harvey⁸, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ³University of Glasgow, Glasgow, United Kingdom, ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁸Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Laboratory biomarkers indicative of cardiac ischemia or dysfunction improve cardiovascular (CV) risk stratification in the general population. Their utility in patients with psoriatic disease…
Abstract Number: 2036 • 2018 ACR/ARHP Annual Meeting
Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis
Ankita Singh¹, Ramnath Misra² and Amita Aggarwal², ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Methotrexate (MTX) is first line of therapy to treat Rheumatoid Arthritis (RA) patients and one third of patients do not respond to this drug.…
Abstract Number: 877 • 2018 ACR/ARHP Annual Meeting
Serum Krebs Von Den Lungen-6 Is a Useful Biomarker for Assessing Activity of Myositis-Associated Interstitial Lung Disease
Satoshi Takanashi¹, Naoshi Nishina², Maho Nakazawa², Yuko Kaneko² and Tsutomu Takeuchi², ¹Division of Rheumatoloy, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of serious organ involvements in idiopathic inflammatory myositis. Krebs von den Lungen-6 (KL-6) is an antigen produced primarily…
Abstract Number: 1356 • 2018 ACR/ARHP Annual Meeting
Increasing Oral Doses of GLPG1972 Administered Daily for 29 Days Show a Strong Target Engagement in Patients with Knee and/or Hip OA
Henri Deckx¹, Simon Hatch², Martine Robberechts¹, Sonia Dupont³, Julie Desrivot³, Hugh Coleman⁴, Staffan Larsson⁵, André Struglics⁵, Ellen van der Aar¹ and Ann Fieuw¹, ¹Galapagos NV, Mechelen, Belgium, ²Galapagos NV, Boston, MA, ³Galapagos SASU, Romainville, France, ⁴CRU, Covance, Daytona Beach, FL, ⁵Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: Osteoarthritis (OA) is characterized by structural changes of the joint, of which degradation of articular cartilage is one of the major signs1. The main…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].